Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the safety and effectiveness of a new treatment called IMGN151 for women with certain types of cancer that have returned after treatment. The cancers being studied include recurrent endometrial cancer and recurrent high-grade serous epithelial ovarian cancer, as well as similar cancers affecting the lining of the abdomen and fallopian tubes. IMGN151 is a special type of medication known as an antibody-drug conjugate, which is designed to target and attack cancer cells more precisely.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's objectives and procedures. The patient must sign an informed consent form to confirm understanding and agreement to participate.

  2. Step 2

    Initial assessment

    The patient will undergo an initial assessment to confirm eligibility. This includes a review of medical history, current health status, and any previous treatments. Blood tests and imaging may be conducted to ensure the patient meets the study criteria.

  3. Step 3

    Dose-escalation phase

    During this phase, the patient will receive IMGN151 intravenously. The purpose is to determine the safest and most effective dose. The patient will be monitored for any side effects or adverse reactions. The frequency and dosage will be adjusted based on the patient's response.

  4. Step 4

    Expansion phase

    In this phase, the patient will continue to receive IMGN151 at the determined dose. The focus is on evaluating the treatment's effectiveness in reducing cancer size or progression. Regular assessments will be conducted to monitor the patient's condition.

  5. Step 5

    Use of eye drops

    The patient will use Pred Forte 1% w/v Eye Drops Suspension and Brimonidine Tartrate 0.2% w/v Eye Drops for conjunctival use. These medications are administered as eye drops to manage any ocular symptoms or side effects. The frequency and duration will be specified by the healthcare provider.

  6. Step 6

    Ongoing monitoring

    Throughout the trial, the patient will have regular check-ups to monitor health status and treatment effects. This includes blood tests, imaging, and other necessary evaluations to ensure safety and effectiveness.

  7. Step 7

    Completion of the trial

    Upon completion of the trial, the patient will undergo a final assessment. This will include a comprehensive review of the treatment's impact on the patient's condition and any long-term effects. The patient will receive guidance on post-trial care and follow-up.

Who can join the trial?

19 criteria

  • Patients must be at least 18 years old.
  • Must have completed any major surgery at least 4 weeks before the first dose of the study drug and have recovered or stabilized from the side effects of prior surgery.
  • Must have adequate blood, liver, and kidney functions. This means:
    • Enough white blood cells without recent use of growth factors.
    • Enough platelets without recent transfusion.
    • Enough hemoglobin without recent blood transfusion.
    • Good kidney function.
    • Liver enzymes within acceptable limits.
    • Normal bilirubin levels, with some exceptions for certain conditions.
    • Enough albumin in the blood.
    • Must be willing and able to sign a consent form and follow the study requirements.
    • Women who can have children must agree to use effective birth control during the study and for at least 28 weeks after the last dose.
    • Women who can have children must have a negative pregnancy test before starting the study drug.
    • Must have a performance status of 0 or 1, which means being fully active or having some restrictions but able to carry out light work.
    • For the Dose-Escalation Phase, must have a confirmed diagnosis of certain types of recurrent cancer and have tried standard treatments without success.
    • For the Expansion Phase, must have a confirmed diagnosis of certain types of recurrent cancer, with specific treatment history and conditions.
    • Must have completed prior cancer treatments within specific time frames before starting the study drug.
    • Must have stabilized or recovered from side effects of previous treatments, except for hair loss.
    • Must have tumors that can be evaluated by imaging tests.
    • Must provide tumor tissue samples for testing.

Who cannot join the trial?

2 criteria

  • Patients who are not female cannot participate in the study.
  • Patients who are not considered part of a vulnerable population cannot participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

IMGN151 is an experimental medication being studied for its potential to treat certain types of cancer. It is an antibody-drug conjugate, which means it combines an antibody with a drug to specifically target and kill cancer cells. In this trial, IMGN151 is being tested in adult patients with recurrent endometrial cancer and recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers. The study aims to determine the safety and tolerability of IMGN151, as well as the most effective dose for future studies.

What is already known about the treatment

IMGN151 – IMGN151 is an investigational medication currently being studied in clinical trials for its potential use in treating recurrent endometrial cancer and recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers. It is administered intravenously, meaning it is given directly into a vein. The medication is an antibody-drug conjugate, which means it combines an antibody with a drug to specifically target and kill cancer cells. This approach aims to deliver the drug directly to the cancer cells, minimizing damage to healthy cells. IMGN151 is still in the early stages of clinical research, focusing on determining its safety, tolerability, and optimal dosing.

Investigated diseases

  • Recurrent Endometrial Cancer

    This type of cancer occurs when cancer cells form in the lining of the uterus and return after treatment. It often involves abnormal bleeding and pelvic pain. The cancer can spread to nearby tissues or distant organs. Over time, it may become more resistant to standard treatments, making it challenging to manage.

  • Recurrent High-Grade Serous Epithelial Ovarian Cancer

    This aggressive form of ovarian cancer originates in the cells on the surface of the ovary and tends to recur after initial treatment. It is characterized by rapid growth and a tendency to spread to other parts of the body. Symptoms may include abdominal bloating, pain, and changes in bowel habits. The cancer often becomes more difficult to treat with each recurrence.

  • Recurrent Primary Peritoneal Cancer

    This cancer is similar to ovarian cancer but starts in the peritoneum, the lining of the abdominal cavity. It can recur after initial treatment, presenting symptoms like abdominal pain and swelling. The disease may spread to other organs within the abdomen. As it progresses, it can become more challenging to control.

  • Recurrent Fallopian Tube Cancer

    This rare cancer begins in the fallopian tubes and can return after treatment. It shares similarities with ovarian cancer, including symptoms like pelvic pain and abnormal bleeding. The cancer may spread to nearby organs or tissues. With recurrence, it often becomes more resistant to therapies.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-506842-22-00Protocol codeIMGN151-1001Estimated enrolment447 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.